{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:40:25Z","timestamp":1792554025651,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hypertrophic scars and keloids, which are abnormalities of fibrosis, often occur in surgical wounds; however, their exact cause and preventive measures are unknown. The administration of dipeptidyl peptidase-4 inhibitors to humans is expected to suppress fibrosis in wounds and minimize hypertrophic scar and keloid formation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study aimed to verify the suppressive effect of dipeptidyl peptidase-4 inhibitors on the formation of hypertrophic scars or keloids using real world data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. It is a retrospective cohort study, and data were extracted from the National Database between April of 2013 and March of 2015. Patients who underwent median sternotomy were included in the study based on their claimed surgical codes. Subjects who were prescribed dipeptidyl peptidase-4 inhibitors constituted the treatment group; subjects who were not prescribed or administered dipeptidyl peptidase-4 inhibitors during that period constituted the nontreatment group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Subjects included 5430 patients throughout Japan (3509 men and 1921 women). Of the 446 subjects who were treated with dipeptidyl peptidase-4 inhibitors within 1 year before the procedure, fewer than 10 (&lt;2 percent) developed either hypertrophic scars or keloids. Of the 4984 subjects who were not treated, 152 (3.05 percent) were at significantly lower risk for hypertrophic scars and keloids (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.04). A logistic regression analysis was performed to adjust for confounding factors, with history of hypertrophic scar formation as the explained variable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study revealed that dipeptidyl peptidase-4 inhibitors suppress the onset of hypertrophic scars or keloids after surgery in humans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL QUESTION\/LEVEL OF EVIDENCE:<\/jats:title>\n            <jats:p>Therapeutic, III.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000006904","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T05:15:12Z","timestamp":1587014112000},"page":"83-89","source":"Crossref","is-referenced-by-count":16,"title":["Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan"],"prefix":"10.1097","volume":"146","author":[{"given":"Hirotsugu","family":"Suwanai","sequence":"first","affiliation":[{"name":"From the Department of Diabetes, Metabolism, Endocrinology, Rheumatology, and Collagen Diseases and the Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University; and the Kanagawa University of Human Services, Faculty of Health and Social Services."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Watanabe","sequence":"additional","affiliation":[{"name":"From the Department of Diabetes, Metabolism, Endocrinology, Rheumatology, and Collagen Diseases and the Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University; and the Kanagawa University of Human Services, Faculty of Health and Social Services."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munemori","family":"Sato","sequence":"additional","affiliation":[{"name":"From the Department of Diabetes, Metabolism, Endocrinology, Rheumatology, and Collagen Diseases and the Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University; and the Kanagawa University of Human Services, Faculty of Health and Social Services."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Odawara","sequence":"additional","affiliation":[{"name":"From the Department of Diabetes, Metabolism, Endocrinology, Rheumatology, and Collagen Diseases and the Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University; and the Kanagawa University of Human Services, Faculty of Health and Social Services."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Matsumura","sequence":"additional","affiliation":[{"name":"From the Department of Diabetes, Metabolism, Endocrinology, Rheumatology, and Collagen Diseases and the Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University; and the Kanagawa University of Human Services, Faculty of Health and Social Services."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"R1-20231015","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/DSS.0000000000001140","article-title":"The effect of tranilast 8% liposomal gel versus placebo on post-cesarean surgical scars: A prospective double-blind split-scar study.","volume":"43","author":"Kohavi","year":"2017","journal-title":"Dermatol Surg"},{"key":"R2-20231015","doi-asserted-by":"crossref","first-page":"aaa2151","DOI":"10.1126\/science.aaa2151","article-title":"Skin fibrosis: Identification and isolation of a dermal lineage with intrinsic fibrogenic potential.","volume":"348","author":"Rinkevich","year":"2015","journal-title":"Science"},{"key":"R3-20231015","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"R4-20231015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2119\/molmed.2009.00153","article-title":"Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies.","volume":"17","author":"Gauglitz","year":"2011","journal-title":"Mol Med"},{"key":"R5-20231015","first-page":"57","article-title":"Median sternotomy scar assessment.","volume":"124","author":"Jina","year":"2011","journal-title":"N Z Med J"},{"key":"R7-20231015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12895-016-0050-5","article-title":"Risk factors of keloids in Syrians.","volume":"16","author":"Shaheen","year":"2016","journal-title":"BMC Dermatol"},{"key":"R8-20231015","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1097\/SAP.0000000000000103","article-title":"Hypertrophic burn scar management: What does the evidence show? A systematic review of randomized controlled trials.","volume":"72","author":"Friedstat","year":"2014","journal-title":"Ann Plast Surg"},{"key":"R9-20231015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1054\/plef.2000.0207","article-title":"Keloids in rural black South Africans. Part 1: general overview and essential fatty acid hypotheses for keloid formation and prevention.","volume":"63","author":"Louw","year":"2000","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R10-20231015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/wrr.12197","article-title":"The link between hypertension and pathological scarring: Does hypertension cause or promote keloid and hypertrophic scar pathogenesis?","volume":"22","author":"Huang","year":"2014","journal-title":"Wound Repair Regen"},{"key":"R11-20231015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mehy.2016.09.024","article-title":"Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis: Keloids and hypertrophic scars may be vascular disorders.","volume":"96","author":"Ogawa","year":"2016","journal-title":"Med Hypotheses"},{"key":"R12-20231015","doi-asserted-by":"crossref","first-page":"112e","DOI":"10.1097\/PRS.0b013e31819a34db","article-title":"Treatment of a postburn keloid scar with topical captopril: Report of the first case.","volume":"123","author":"Ardekani","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R13-20231015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000051812","article-title":"Prevention and treatment of keloids with intralesional verapamil.","volume":"204","author":"D\u2019Andrea","year":"2002","journal-title":"Dermatology"},{"key":"R14-20231015","first-page":"105","article-title":"Morphological and immunochemical differences between keloid and hypertrophic scar.","volume":"145","author":"Ehrlich","year":"1994","journal-title":"Am J Pathol"},{"key":"R15-20231015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.metabol.2016.03.010","article-title":"Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.","volume":"65","author":"Hirano","year":"2016","journal-title":"Metabolism"},{"key":"R16-20231015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2840-13-32","article-title":"The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.","volume":"13","author":"Zeng","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"R17-20231015","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/eji.200323469","article-title":"Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.","volume":"33","author":"Yan","year":"2003","journal-title":"Eur J Immunol"},{"key":"R18-20231015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers.","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther"},{"key":"R19-20231015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/db17-0934","article-title":"DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring.","volume":"67","author":"Long","year":"2018","journal-title":"Diabetes"},{"key":"R20-20231015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/PRS.0000000000002634","article-title":"Dipeptidyl peptidase-4, wound healing, scarring, and fibrosis.","volume":"138","author":"Hu","year":"2016","journal-title":"Plast Reconstr Surg"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:16:17Z","timestamp":1697343377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000006904","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,15]]}}}